Examples of foods that are high in L-serine include soy products like edamame and tofu, sweet potatoes, pork products, turkey, and eggs.
L-serine is involved in many of the core functions of our bodies including providing building blocks for proteins, supporting cell membrane structure, and supporting brain and nerve functions. Studies[1] have shown that in places where people have a high dietary intake of L-serine, the incidences of neurodegenerative diseases are lower.
The first clues that L-serine might be neuroprotective came from a landmark study[2] by Brain Chemistry Labs and the University of Technology Sydney. Scientists showed that L-serine blocked BMAA, the molecule implicated in ALS, ALS/Parkinsonism Dementia Complex, and Alzheimer’s disease, from killing human neuronal cells in culture. Follow-up studies[3][4][5][6] provided more evidence for L-serine’s neuroprotective effect.
These findings led directly to a clinical trial[7] for L-serine as a possible treatment for ALS. Intended as a safety trial, results were very encouraging, leading to compelling evidence that L-serine might be neuroprotective in preventing and treating neurodegenerative diseases.
Brain Chemistry Labs, in collaboration with Houston Methodist Research Institute in Texas, is currently completing a clinical trial for L-serine as a treatment for Mild Cognitive Impairment (MCI), a precursor to Alzheimer’s disease. The aim of this study is to see if L-serine, taken orally, can prevent the conversion to Alzheimer’s Disease. The results of this trial are expected in 2027.
Future work will test the effectiveness of L-serine in larger human clinical trials and against other neurodegenerative diseases.
Join us in supporting this highly impactful work.
- 1.
Cox PA, Metcalf JS. Traditional Food Items in Ogimi, Okinawa: l-Serine Content and the Potential for Neuroprotection. Curr Nutr Rep. 2017. doi:10.1007/s13668-017-0191-0
- 2.
Dunlop RA, Cox PA, Banack SA, Rodgers KJ. The non-protein amino acid BMAA is incorporated into human proteins in place of L-serine causing protein misfolding and aggregation. PLOS ONE. 2013;8:e75376. doi:10.1371/journal.pone.0075376
- 3.
Cox PA, Davis DA, Mash DC, Metcalf JS, Banack SA. Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain. Proc R Soc Lond B Biol Sci. 2016;283. PDF
- 4.
Davis DA, Cox PA, Banack SA, Lecusay PD, Garamszegi SP, Hagan MJ, et al. L-serine reduces spinal cord pathology in a vervet model of preclinical ALS/MND. J Neuropathol Exp Neurol. 2020;79:396–406. doi:10.1093/jnen/nlaa002
- 5.
Dunlop RA, Powell JT, Metcalf JS, Guillemin GJ, Cox PA. l-Serine-Mediated Neuroprotection Includes the Upregulation of the ER Stress Chaperone Protein Disulfide Isomerase (PDI). Neurotox Res. 2017. doi:10.1007/s12640-017-9817-7
- 6.
Dunlop RA, Carney JM. Mechanisms of l-Serine-Mediated Neuroprotection Include Selective Activation of Lysosomal Cathepsins B and L. Neurotox Res. 2020. doi:10.1007/s12640-020-00168-2
- 7.
Levine TD, Miller RG, Bradley WG, Moore DH, Saperstein DS, Flynn LE, et al. Phase I clinical trial of safety of L-serine for ALS patients. Amyotroph Lateral Scler Front Degener. 2016;:1–5. doi:10.1080/21678421.2016.1221971
MCI
A trial of oral L-serine for Mild Cognitive Impairment, a precursor to Alzheimer’s disease, with Houston Methodist Research Institute. Results expected in 2027.
- PartnerHouston Methodist
- Phase I, ALSCompleted
- MCI trialCompleting
- NextLarger trials
